Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free AEHA Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Aesther Healthcare Acquisition (AEHA) Competitors

Aesther Healthcare Acquisition logo
Compare

AEHA vs. SYRS, ARDS, TRVN, AMPE, and EVLO

Should you be buying Aesther Healthcare Acquisition stock or one of its competitors? The main competitors of Aesther Healthcare Acquisition include Syros Pharmaceuticals (SYRS), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical preparations" industry.

How does Aesther Healthcare Acquisition compare to Syros Pharmaceuticals?

Aesther Healthcare Acquisition (NASDAQ:AEHA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Aesther Healthcare Acquisition has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Aesther Healthcare Acquisition has higher earnings, but lower revenue than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aesther Healthcare AcquisitionN/AN/A-$560KN/AN/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Aesther Healthcare Acquisition's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aesther Healthcare AcquisitionN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

78.6% of Aesther Healthcare Acquisition shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 19.8% of Aesther Healthcare Acquisition shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Aesther Healthcare Acquisition's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aesther Healthcare Acquisition Neutral
Syros Pharmaceuticals Neutral

Summary

Aesther Healthcare Acquisition beats Syros Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aesther Healthcare Acquisition compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Aesther Healthcare Acquisition (NASDAQ:AEHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Aridis Pharmaceuticals has a beta of 49.48, meaning that its stock price is 4,848% more volatile than the S&P 500. Comparatively, Aesther Healthcare Acquisition has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03
Aesther Healthcare AcquisitionN/AN/A-$560KN/AN/A

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Aesther Healthcare Acquisition N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Aesther Healthcare Acquisition shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Aesther Healthcare Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Aesther Healthcare Acquisition'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Aesther Healthcare Acquisition Neutral

Summary

Aesther Healthcare Acquisition beats Aridis Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

How does Aesther Healthcare Acquisition compare to Trevena?

Trevena (NASDAQ:TRVN) and Aesther Healthcare Acquisition (NASDAQ:AEHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Trevena has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Aesther Healthcare Acquisition has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Aesther Healthcare Acquisition has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Aesther Healthcare AcquisitionN/AN/A-$560KN/AN/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Aesther Healthcare Acquisition N/A N/A N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Aesther Healthcare Acquisition'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Aesther Healthcare Acquisition Neutral

13.6% of Trevena shares are owned by institutional investors. Comparatively, 78.6% of Aesther Healthcare Acquisition shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 19.8% of Aesther Healthcare Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aesther Healthcare Acquisition beats Trevena on 4 of the 6 factors compared between the two stocks.

How does Aesther Healthcare Acquisition compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Aesther Healthcare Acquisition (NASDAQ:AEHA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Aesther Healthcare AcquisitionN/AN/A-$560KN/AN/A

Ampio Pharmaceuticals has a beta of 7.65, suggesting that its stock price is 665% more volatile than the S&P 500. Comparatively, Aesther Healthcare Acquisition has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Aesther Healthcare Acquisition shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Aesther Healthcare Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Aesther Healthcare Acquisition N/A N/A N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Aesther Healthcare Acquisition'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Aesther Healthcare Acquisition Neutral

Summary

Aesther Healthcare Acquisition beats Ampio Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

How does Aesther Healthcare Acquisition compare to Evelo Biosciences?

Aesther Healthcare Acquisition (NASDAQ:AEHA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aesther Healthcare AcquisitionN/AN/A-$560KN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Aesther Healthcare Acquisition has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

78.6% of Aesther Healthcare Acquisition shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 19.8% of Aesther Healthcare Acquisition shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Aesther Healthcare AcquisitionN/A N/A N/A
Evelo Biosciences N/A N/A N/A

In the previous week, Evelo Biosciences had 1 more articles in the media than Aesther Healthcare Acquisition. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Aesther Healthcare Acquisition. Evelo Biosciences' average media sentiment score of 0.64 beat Aesther Healthcare Acquisition's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Aesther Healthcare Acquisition Neutral
Evelo Biosciences Positive

Summary

Aesther Healthcare Acquisition and Evelo Biosciences tied by winning 3 of the 6 factors compared between the two stocks.

Get Aesther Healthcare Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEHA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEHA vs. The Competition

Export
MetricAesther Healthcare AcquisitionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$883.41M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E RatioN/A1.7129.2527.07
Price / SalesN/A119.23504.6873.43
Price / CashN/A20.0743.3053.90
Price / Book0.007.609.676.69
Net Income-$560K-$4.80M$3.55B$332.64M

Aesther Healthcare Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEHA
Aesther Healthcare Acquisition
N/A$0.00
flat		N/A-100.0%$4KN/AN/A2,021
SYRS
Syros Pharmaceuticals
N/A$0.00
+150.0%		N/A-99.4%$13K$386KN/A120
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+2,700.0%$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/A-99.1%$11K$443KN/A40
AMPE
Ampio Pharmaceuticals
N/A$0.01
flat		N/A+550.0%$6KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AEHA) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel